FIT NS-Prime is a fecal immunochemical test system, which consists of discrete clinical chemistry automatic analyzer NS-Prime, its dedicated reagents, and well thought-out specimen collection container. One of the advantages of FIT NS-Prime system is to be able to perform multiple assays simultaneously using one specimen collection container. In addition to hemoglobin, transferrin assay is available, and calprotectin assay kit will soon be available (will be launched in 2020), which is already approved in Japan.
Many new features are added while retaining the most popular features of the previous model NS-Plus.
Advanced features include:
・Easier Management with Barcodes Calibrators, controls and reagents all barcoded for quick, accurate hassle-free registration ・Improved Reproducibility More accurate dispensing for much higher reproducibility ・Ten-rack Tray Ten-rack tray added as a standard feature allows simultaneous loading of 100 samples ・Simultaneous Multiple Assay For multiple combination screening ・Up to Five Days of Continued Placement Built-in refrigeration allows reagents to be left in rack up to 5 days
AA01 is a discrete clinical chemistry automatic analyzer for FIT, whose size is smaller and whose throughput is lower than its former model NS-Prime. Operation is very easy, just set reagents and samples, and push the start button. So this is suitable for not only for users who have a low number of samples but also for users who have not experienced FIT. We collaborated to develop AA01 with Arkray Inc., and the following urine tests, which cannot be assayed on NS-Prime, are available on it as well as the FOB tests. Current available tests are as follows.
Fecal Tests: Hemoglobin and Transferrin (and Calprotectin will be launched in 2020 in EU, that will be available in October 2019 in Japan)
Urine Tests: Glucose, Protein, Creatinine, and Albumin
Cystatin C is a renal dysfunction marker. This evidence-based endogenous marker of glomerular filtration rate (GFR) is not affected by age, muscle mass, nutritional status, or malignancy, unlike the conventional marker, serum creatinine. Besides, Cystatin C detects reduction of GFR in the earlier stage than creatinine.
Features of Alfresa Auto Cystatin C
Colloidal gold method Can be used in various clinical chemistry automatic analyzers Ready-to-use Simple, fast, and non-invasive assay Assigned with the international standard material, ERM-DA471/IFCC